United Therapeutics (NASDAQ:UTHR) CEO Martine Rothblatt Sells 8,000 Shares

Key Points

• United Therapeutics CEO Martine Rothblatt sold 8,000 shares of stock at an average price of $398.55, amounting to a total of $3,188,400, which represents a 98.40% decrease in their ownership.
• United Therapeutics reported earnings of $6.41 per share for the last quarter, missing estimates by $0.39, with revenues of $798.60 million.
• Analyst price targets for United Therapeutics have been raised significantly, with ratings indicating a "Moderate Buy" and a consensus price target of $438.85.

United Therapeutics Corporation (NASDAQ:UTHR - Get Free Report) CEO Martine Rothblatt sold 8,000 shares of the firm's stock in a transaction dated Tuesday, September 9th. The shares were sold at an average price of $398.55, for a total transaction of $3,188,400.00. Following the transaction, the chief executive officer owned 130 shares of the company's stock, valued at $51,811.50. This trade represents a 98.40% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.

United Therapeutics Stock Performance

NASDAQ:UTHR traded down $7.30 during mid-day trading on Wednesday, hitting $396.50. 650,182 shares of the company's stock traded hands, compared to its average volume of 565,346. The firm's 50 day simple moving average is $312.09 and its 200 day simple moving average is $306.29. United Therapeutics Corporation has a 1 year low of $266.98 and a 1 year high of $436.95. The company has a market cap of $17.89 billion, a PE ratio of 15.48, a price-to-earnings-growth ratio of 6.02 and a beta of 0.62.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last posted its earnings results on Wednesday, July 30th. The biotechnology company reported $6.41 earnings per share for the quarter, missing the consensus estimate of $6.80 by ($0.39). The business had revenue of $798.60 million for the quarter, compared to analysts' expectations of $802.13 million. United Therapeutics had a net margin of 40.36% and a return on equity of 18.73%. The business's revenue was up 11.7% compared to the same quarter last year. During the same quarter last year, the business posted $5.85 earnings per share. On average, research analysts expect that United Therapeutics Corporation will post 24.48 earnings per share for the current fiscal year.

Institutional Investors Weigh In On United Therapeutics

A number of institutional investors have recently bought and sold shares of UTHR. Chung Wu Investment Group LLC purchased a new stake in United Therapeutics in the second quarter valued at approximately $29,000. WealthCollab LLC grew its holdings in United Therapeutics by 55.9% in the second quarter. WealthCollab LLC now owns 106 shares of the biotechnology company's stock valued at $30,000 after purchasing an additional 38 shares during the period. Rakuten Securities Inc. grew its holdings in United Therapeutics by 76.7% in the second quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company's stock valued at $30,000 after purchasing an additional 46 shares during the period. SVB Wealth LLC purchased a new stake in United Therapeutics in the first quarter valued at approximately $32,000. Finally, Geneos Wealth Management Inc. grew its holdings in United Therapeutics by 141.7% in the first quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company's stock valued at $45,000 after purchasing an additional 85 shares during the period. 94.08% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

UTHR has been the subject of a number of recent research reports. Cantor Fitzgerald lifted their price target on shares of United Therapeutics from $405.00 to $525.00 and gave the stock an "overweight" rating in a report on Wednesday. UBS Group lifted their price target on shares of United Therapeutics from $415.00 to $560.00 and gave the stock a "buy" rating in a report on Thursday, September 4th. Oppenheimer lifted their price target on shares of United Therapeutics from $510.00 to $575.00 and gave the stock an "outperform" rating in a report on Friday, September 5th. Jefferies Financial Group lifted their price target on shares of United Therapeutics from $432.00 to $564.00 and gave the stock a "buy" rating in a report on Tuesday, September 2nd. Finally, HC Wainwright raised their price target on United Therapeutics from $400.00 to $500.00 and gave the stock a "buy" rating in a research note on Friday, September 5th. Nine research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $438.85.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.